DOI: 10.1016/J.BIOPSYCH.2013.08.025
关键词:
摘要: Given the relative inability of currently available antipsychotic treatments to adequately provide sustained recovery and improve quality life for patients with schizophrenia, new treatment strategies are urgently needed. One way therapeutic development process may be an increased use biomarkers in early clinical trials. Reliable that reflect aspects disease pathophysiology can used determine if potential engaging their desired biological targets. This review evaluates three neuroimaging biomarkers: hippocampal hyperactivity, gamma-band deficits, default network abnormalities. These deficits have been widely replicated illness, correlate measures positive symptoms, consistent models pathology, shown initial promise as response studies strategies. Two key features these a guiding rationale focus this review, not dependent upon patients' performance specific cognitive tasks they analogues animal greatly increasing appeal biomarkers. Using such those proposed here establish having intended effect humans facilitate schizophrenia.